Semin Thromb Hemost 2017; 43(01): 092-100
DOI: 10.1055/s-0036-1597293
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation

Adriana Ines Woods
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Ana Catalina Kempfer
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Juvenal Paiva
2   Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Analia Sanchez-Luceros
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
2   Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Emilse Bermejo
2   Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Roberto Chuit
3   Instituto de Investigaciones Epidemiológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Maria Fabiana Alberto
2   Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Alicia Noemi Blanco
2   Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
,
Maria Angela Lazzari
1   Laboratorio de Hemostasia y Trombosis, IMEX-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2016 (online)

Abstract

von Willebrand disease type 2B (VWD2B) expresses gain-of-function mutations that enhance binding of an individual's von Willebrand factor (VWF) to its platelet ligand, glycoprotein Ib (GPIb), and which are usually identified by increased ristocetin-induced platelet aggregation (RIPA). We describe here the phenotypic profile of 38 genotypically selected VWD2B-affected family members (AFMs) belonging to 19 unrelated families. Major bleeding was observed in 68.4% of AFMs (previous to their diagnosis and registered by lifetime interviews), with a total of 46 episodes (1.21/patient), and was found to be highly related to the individual bleeding score and presence of thrombocytopenia, but otherwise unrelated to other laboratory parameters. Excessive muco-cutaneous bleeding symptoms were often reported, the most frequent of which comprised menorrhagia, epistaxis, easy bruising, and bleeding after teeth extraction/in oral cavity. Eight unaffected family members were also studied. The prevalence of VWD2B within families was 0.826, and the penetrance of mutations was complete, making it mandatory to study entire family sets to complete diagnostic profiles. Seven heterozygous missense mutations were found, the most common being p.V1316M. In the p.R1308C group, 75% of the AFMs showed absence of RIPA at 0.5 mg/mL, 66.6% of whom had VWF:RCo < 10 IU/dL, and 50% of whom had VWF:CB < 10 IU/dL. In the p.S1310F group, none of the AFMs had VWF:RCo/VWF:Ag < 0.6 (RCo/Ag), but 100% had VWF:CB/VWF:Ag < 0.6/(CB/Ag). Patients with p.P1266L and p.R1304V were characterized as atypical VWD2B. Two de novo mutations were found in four AFMs belonging to two families. We also describe a novel mutation: p.Y1258C. Of our patients, 70.5% had O blood group. In conclusion, a normal RCo/Ag and a negative RIPA at 0.5 mg/mL do not necessarily rule out a diagnosis of VWD2B.

 
  • References

  • 1 Sadler JE, Budde U, Eikenboom JC , et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
  • 2 Rayes J, Hommais A, Legendre P , et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost 2007; 5 (2) 321-328
  • 3 Moll S, Lazarowski AR, White II GC. Giant platelet disorder in a patient with type 2B von Willebrand's disease. Am J Hematol 1998; 57 (1) 62-67
  • 4 Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica 2009; 94 (5) 610-615
  • 5 Nurden P, Debili N, Vainchenker W , et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 2006; 108 (8) 2587-2595
  • 6 Nurden P, Gobbi G, Nurden A , et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115 (13) 2649-2656
  • 7 Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68 (1) 149-156
  • 8 Holmberg L, Berntorp E, Donnér M, Nilsson IM. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68 (3) 668-672
  • 9 Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest 1993; 91 (5) 2169-2177
  • 10 Casari C, Berrou E, Lebret M , et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest 2013; 123 (12) 5071-5081
  • 11 Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009; 113 (14) 3348-3351
  • 12 Takimoto Y, Imanaka F. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma. Int J Hematol 1999; 70 (2) 127-131
  • 13 Casonato A, Gallinaro L, Cattini MG , et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica 2010; 95 (8) 1366-1372
  • 14 Rodeghiero F, Castaman G, Tosetto A , et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3 (12) 2619-2626 [ Erratum in: J Thromb Haemost 2006;4:925]
  • 15 Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7 (8) 1418-1421
  • 16 Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85 (6) 977-982
  • 17 Schulman S, Kearon C ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (4) 692-694
  • 18 Mielke Jr CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34 (2) 204-215
  • 19 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-219
  • 20 Taylor LD. The application of the biotin/avidin system to the von Willebrand factor antigen immunoassay. Thromb Haemost 1988; 59 (2) 251-254
  • 21 Borchiellini A, Fijnvandraat K, ten Cate JW , et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88 (8) 2951-2958
  • 22 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34 (1) 306-308
  • 23 Mannucci PM, Lombardi R, Bader R , et al. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984; 64 (3) 614-621
  • 24 Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9 (3) 303-308
  • 25 Farias C, Kempfer AC, Blanco A, Woods A, Lazzari MA. Visualization of the multimeric structure of von Willebrand factor by immunoenzymatic stain using avidin-peroxidase complex instead of avidin-biotin peroxidase complex. Thromb Res 1989; 53 (5) 513-518
  • 26 Woods AI, Sánchez-Luceros A, Kempfer AC , et al. C1272F: a novel type 2A von Willebrand's disease mutation in A1 domain; its clinical significance. Haemophilia 2012; 18 (1) 112-116
  • 27 Agresti A, Coull BA. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat 1998; 52: 119-126
  • 28 Federici AB, Mannucci PM, Castaman G , et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (3) 526-534
  • 29 Szántó T, Schlammadinger A, Salles I , et al. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb Haemost 2007; 98 (1) 251-254
  • 30 ISTH-SSC VWF Online Database. . Available at: www.ragtimedesign.com/vwf/mutation/ ; Accessed March 18, 2016
  • 31 Woods AI, Sánchez-Luceros A, Kempfer AC , et al. p.M1304V: a new mutation in the a1 domain associated to atypical von Willebrand 2B phenotype. J Thromb Haemost 2012; 11 (Suppl. 03) 102
  • 32 Sadler JE, Mannucci PM, Berntorp E , et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84 (2) 160-174
  • 33 Murray EW, Giles AR, Lillicrap D. Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease. Am J Hum Genet 1992; 50 (1) 199-207
  • 34 Holmberg L, Karpman D, Isaksson C, Kristoffersson AC, Lethagen S, Schneppenheim R. Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease. Thromb Haemost 1998; 79 (4) 718-722
  • 35 Lester WA, Guilliatt AM, Surdhar GK , et al. Inherited and de novo von Willebrand disease ‘Vicenza’ in UK families with the R1205H mutation: diagnostic pitfalls and new insights. Br J Haematol 2006; 135 (1) 91-96
  • 36 Ahmad F, Oyen F, Jan R, Budde U, Schneppenheim R, Saxena R. Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease. Haemophilia 2014; 20 (4) e311-e317
  • 37 Acuna-Hidalgo R, Bo T, Kwint MP , et al. Post-zygotic Point mutations are an underrecognized source of de novo genomic variation. Am J Hum Genet 2015; 97 (1) 67-74
  • 38 Yang G, Chen Z, Zhang W, Liu Z, Zhao J. Novel mutations in CRYGD are associated with congenital cataracts in Chinese families. Sci Rep 2016; 6: 18912
  • 39 Armaroli A, Trabanelli C, Scotton C , et al. Paternal germline mosaicism in collagen VI related myopathies. Eur J Paediatr Neurol 2015; 19 (5) 533-536
  • 40 Nemirovsky SI, Córdoba M, Zaiat JJ , et al. Whole genome sequencing reveals a de novo SHANK3 mutation in familial autism spectrum disorder. PLoS One 2015; 10 (2) e0116358
  • 41 Aulitzky A, Friedrich K, Gläser D , et al. A complex form of hereditary spastic paraplegia in three siblings due to somatic mosaicism for a novel SPAST mutation in the mother. J Neurol Sci 2014; 347 (1-2) 352-355
  • 42 Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33 (8) 727-744
  • 43 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (6) 1043-1054
  • 44 Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Mannucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost 2005; 3 (12) 2689-2694
  • 45 Szántó T, Schlammadinger A, Staelens S , et al. The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha. Thromb Haemost 2007; 98 (1) 178-185
  • 46 Flood VH, Gill JC, Morateck PA , et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116 (2) 280-286
  • 47 Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost 2002; 28 (2) 191-202
  • 48 Castaman G, Federici AB. Type 2B von Willebrand disease: a matter of plasma plus platelet abnormality. Semin Thromb Hemost 2016; 42 (5) 478-482
  • 49 Ozeki M, Kunishima S, Kasahara K , et al. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers. Thromb Res 2010; 125 (2) e17-e22
  • 50 Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda, MD: National Center for Biotechnology Information (US); 2005: Chap 2